3-Dimensional Pharmaceuticals Inc., of Yardley, Pa., appointed Brian MacDonald vice president, development, and William Claypool to its board.
Amgen Inc., of Thousand Oaks, Calif., named Beth Seidenberg senior vice president, development.
Antigenics Inc., of New York, appointed Russell Herndon president and chief operating officer.
AnVil Informatics Inc., of Lowell, Mass., appointed John Hotchkiss chief technology officer.
AtheroGenics Inc., of Atlanta, promoted Charles Deignan to senior director of finance and administration.
Biopure Corp., of Cambridge, Mass., appointed Richard Crout to its board.
CDP Sofinov, of Montreal, formed a scientific advisory committee consisting of Thomas Hudson, David Kaplan, Stephen Kish, Ronald Saldarini, William Scott, Francis Tally and Harold Wodlinger.
Cephalon Inc., of West Chester, Pa., said Alain Aragues was appointed president and director general of Cephalon’s subsidiary, Laboratoire L. Lafon, of Paris.
ChemCodes Inc., of Research Triangle Park, N.C., added Steve Holdaway as chief operating officer and Brett Farabaugh as vice president of finance.
GenVec Inc., of Gaithersburg, Md., elected Harold Werner to its board.
IDEC Pharmaceuticals Corp., of San Diego, promoted William Rohn to president and chief operating officer.
Metabolex Inc., of Hayward, Calif., appointed John Blume vice president of strategic technologies and added Gary Titus as senior director of finance.
NitroMed Inc., of Bedford, Mass., appointed Jerry Karabelas to its board.
Oxxon Pharmaccines Ltd., of Oxford, UK, appointed Joseph Sinkule director of operations.
Panacea Pharmaceuticals Inc., of Rockville, Md., added James Willson to its clinical advisory board.
Panacos Pharmaceuticals Inc., of Gaithersburg, Md., appointed Sandra Nusinoff Lehrman to its board.
Paradigm Genetics Inc., of Research Triangle Park, named Leroy Hood to its board.
Rx Communications Group LLC, of New York, added Paula Schwartz as vice president.
Samaritan Pharmaceuticals Inc., of Las Vegas, and Samaritan Laboratories, School of Medicine, Georgetown University, added Laurent Lecanu to its research team.
Transkaryotic Therapies Inc., of Cambridge, Mass., appointed David Pendergast senior vice president, quality and analytical development; Neil Kirby vice president, global regulatory affairs; and Suzanne Bruhn vice president, program management.